Kornimate/medical-research-clean huggingface dataset:
a long-term safety study of ozurdex® in clinical practice

Conditions: Retinal Vein Occlusion; Macular Edema; Uveitis, Posterior

Summary: this study is a multicenter, prospective, observational study to evaluate the long-term safety of ozurdex® in patients with macular oedema following central retinal vein occlusion (crvo) or branch retinal vein occlusion (brvo) or patients with non-infectious posterior segment uveitis in real-world clinical practice.


Eligibility criteria:
inclusion criteria: * macular oedema following either brvo or crvo or non-infectious uveitis * requires treatment with ozurdex® exclusion criteria: * current participation in any clinical study
s-equol in alzheimer's disease (sead) trial

Conditions: Alzheimer's Disease

Summary: the purpose of this study is to determine if s-equol could benefit persons with alzheimer's disease (ad).

alzheimer's disease (ad) is a progressive brain disorder which causes memory and thinking problems. the exact cause of ad is unknown. researchers believe mitochondria (the part of your cells that produces energy) might be linked to symptoms of ad. some studies have shown that patients with alzheimer's disease have reduced mitochondrial activity or have fewer mitochondria present in neurons. in this study, it is believed that by targeting mitochondria, we might learn more about its influence on ad symptoms. mitochondria have a receptor site for estrogen (a hormone) called estrogen receptor β (erβ). when estrogen attaches to this site, it promotes mitochondrial function. studies have also suggested erβ stimulation can cause cells to create new mitochondria. more mitochondria, or increased activity of existing mitochondria, in the cell might have an impact on patients with alzheimer's disease. one way to measure this increase in function is to look for the presence of an enzyme called cox in your blood. if a drug increases mitochondrial function, there will be an increase in cox concentration in the bloodstream. by doing this study we hope to learn if s-equol, a compound that acts like estrogen in the body, causes such an increase in mitochondrial activity. we also hope to determine the tolerability of a therapeutic dose of s-equol. it is our goal to advance the understanding of ad, particularly in women.

Eligibility criteria:
inclusion criteria: * very mild (cdr 0.5) or mild (cdr 1) ad at time of last ku adc assessment * have a study partner * speak english as primary language exclusion criteria: * no viable study partner * report a potentially confounding, serious medical risk such as type 1 diabetes, cancer, or a recent cardiac event (i.e. heart attack, angioplasty, etc.) * use any type of estrogen replacement therapy

Keywords: s-equol cox activity
the effect of 12-week dietary intake of lutein on minimal erythema dose and other skin parameters

Conditions: Minimal Erythema Dose; Skin Viscoelasticity; Dermis Density

Summary: the double-center, randomized, placebo-controlled, one-period effectiveness study will include 30 subjects (women, aged between 25 to 55 years, fitzpatrick phototype ii and iii). subjects will be divided in two groups, 15 in each. one group (test group) will receive investigational product - lutein syrup (4 mg/ml; daily dose 20 mg) and the other (placebo group) placebo syrup. participants will test continuous administration of placebo or investigational product for 12 weeks in order to demonstrate and assess multiple-dose effects. the primary objective is to assess the photoprotective potential of the investigational product in relation to placebo product. the secondary objectives are to assess effects of investigational product on dermis density and skin viscoelasticity after 12 weeks of dietary supplementation.


Eligibility criteria:
inclusion criteria: * caucasian female volunteers aged between 25 and 55 years at the time of the signature of informed consent form (icf), * signed informed consent form (icf), * fitzpatrick skin phototypes ii and iii, * no skin pigmentation disorders, * in good health condition, * willingness to avoid a consumption of any food supplements containing carotenes or other antioxidants during the study, * willingness to avoid the sun, tanning beds and tanning products on the gluteal area during the study, * willingness to follow all study procedures and keeping a diary for during the study (to follow their compliance and palatability), * no changes in dietary habits or dietary supplements in last month prior to inclusion. * no changes in cosmetic facial and body care routine in last month prior to inclusion on measurement areas. exclusion criteria: * pregnancy or breastfeeding, * known or suspected allergy to any ingredient of the tested products or uv radiation, * changes in dietary habits and dietary supplementation in last month prior to inclusion, * veganism, * changes in cosmetic facial and body care routine in last month prior to inclusion. * diagnosed and uncontrolled/untreated/unregulated disease, * any clinically significant history of serious metabolic disease, digestive tract disease, liver disease, kidney disease, haematological disease. * acute skin diseases, * regular consumption of food supplements containing carotenoids or other antioxidants in last month before inclusion into the study. * invasive rejuvenation treatments (e.g. needle rollers, needle mesotherapy, deep/medium-deep chemical peels etc.) in last 6 months prior to study entry, * non-invasive rejuvenation treatments (e.g. radiofrequency, electrotherapy, ultrasound therapy) in last 2 months prior to study entry, * gluteal hyperpigmentation, * mental incapacity that precludes adequate understanding or cooperation
clinical features and rehabilitation effect in patients with stroke

Conditions: Stroke

Summary: dosage of rehabilitation therapy is a key factor in promoting motor functional recovery after stroke. to date, what is not yet known are the clinical features (e.g. the neurological profile, clinical history, motor, language and cognitive abilities), which allow the clinician to predict the recovery potential of a patient before rehabilitation, based on both the initial assessment and the various treatment pathways available in the national health system. for these reasons, the study aims to explore clinical features and potential effect of rehabilitation dose that could influence upper limb motor recovery

dosage of rehabilitation therapy is a key factor in promoting motor functional recovery after stroke. moreover, even though recent evidence has shown that cognitive abilities may support motor recovery, the relationship between cognitive-linguistic and motor skills in stroke patients is still a matter of research. regarding the dose of intervention, in trials in which patients underwent 6 hours of rehabilitation per day, functional improvements in the upper limb reached clinically relevant levels, up to a difference of 8-11 points on the fugl-meyer upper extremity. to date, evidence of clinical (e.g. motor, cognitive-linguistic and neurological) and rehabilitation features that may influence upper limb recovery are still missing. therefore, this study aims to retrospectively explore whether there is a relationship between clinical features and upper limb recovery after rehabilitation in stroke patients.

Eligibility criteria:
inclusion criteria: * age \> 18 years * first-ever unilateral cortical-subcortical stroke, (ischemic or haemorrhagic) * completed at least 4 weeks of rehabilitation * preserved ability or possibility to provide informed consent. exclusion criteria: * cerebellar or bilateral stroke * unstable medical conditions; * diagnosis of other neurological and/or psychiatric diseases in addition to stroke; * traumatic brain injury; * not released informed consent

Keywords: rehabilitation upper limb cognitive functions motor function
gloria-af registry program (phase ii/iii)

Conditions: Stroke; Atrial Fibrillation

Summary: in this part of the registry program patients with non-valvular atrial fibrillation (af) at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events. for administrative purposes the study is divided into three protocol numbers: 1160.129 for all non-eu (european union) and non-eea (european economic area) countries, 1160.136 for eu and eea countries and 1160.171 for switzerland. the total number of patients enrolled in three protocols is estimated to be 48,000 patients, and all these patients will be included in the data analysis for study 1160.129.


Eligibility criteria:
inclusion criteria: 1) patients newly diagnosed with non-valvular atrial fibrillation (nvaf) at risk for stroke. further inclusion criteria apply exclusion criteria: 1. presence of any mechanical heart valve, or valve disease that is expected to require valve replacement intervention; 2. patients who have received more than 60 days of vitamin k antagonist (vka) treatment in their lifetime; 3. af with a generally reversible cause; 4. patients with a medical condition other than atrial fibrillation for which chronic use of an oral anticoagulant (for example, a vka) is indicated. further exclusion criteria apply
improved adherence to c. difficile isolation protocols through improved education methods

Conditions: Bacterial Infection; Clostridium Difficile

Summary: this clinical trial studies how well inter-disciplinary educational methods work in improving adherence to isolation protocols in patients with clostridium (c.) difficile infections. an inter-disciplinary educational method may help to prevent the spread of infection.

primary objectives: i. to lower rates of c. difficile transmission through improved adherence to recommended isolation protocols. secondary objectives: i. improve resident knowledge of infection control procedures and engagement in quality improvement initiatives. outline: residents and nurses are given a short presentation on isolation protocols for diarrhea and enteric pathogens approved by infection control and covering their recommendations. after completion of study, residents and nurses complete post-tests to determine the effectiveness of the training every 6 months.

Eligibility criteria:
patient criteria inclusion criteria: * patient on the gynecologic oncology service * admitted to seidman 6th floor of the seidman cancer center * diarrhea or clinical concern for c. difficile infection exclusion criteria: * none medical staff criteria: inclusion criteria: * any resident or nurse treating a patient meeting the above criteria exclusion criteria: * none

Keywords: clostridium difficile c. difficile adherence
the relationship between preoperative levels of ionized magnesium and risk of acute kidney injury after cardiac surgery

Conditions: Magnesium Disorder

Summary: detection the relationship between preoperative ionized magnesium levels and the risk of acute kidney injury after cardiac surgery.

acute kidney injury (aki) is a major medical problem that is of particular concern after cardiac surgery. the reported prevalence of cardiac surgery-associated acute kidney injury (csa-aki) is up to 30% and is independently associated with an increase of morbidity and mortality .so this study is for measuring preoperative ionized magnesium levels of patients who will undergo cardiac surgeries then measuring postoperative serum creatinine, bun and urine output to detect if they developed aki or not and if there is a relationship between the post cardiac surgery aki and preoperative ionized magnesium levels.

Eligibility criteria:
inclusion criteria: 1. patients more than or equal 18 yrs. 2. patients undergoing cardiac surgery between july 2023 and july 2024 exclusion criteria: 1. patients with known kidney disease. 2. patients less than 18 yrs
patient registry of posner-schlossman syndrome

Conditions: Posner Schlossman Syndrome

Summary: posner-schlossman syndrome, or glaucomatocyclitic crisis, is a condition characterized by recurrent, acute attacks of mild, nongranulomatous, anterior uveitis accompanied by markedly elevated intraocular pressure. most of patients are the 20 to 50-year-old young adults, with unilateral eye involvement. pss was originally deemed benign, but is now recognized as a relatively rare cause of chronic secondary glaucoma,especially in patients with recurrent episodes. this relatively rare disease is likely the result of the infections of a variety of organisms, and the bulk of literature supports the cytomegalovirus (cmv) as the leading cause. this study is an observational study that does not interfere with the normal clinical diagnosis and treatment process. the investigators in this study focus on observing the clinical symptoms and outcome of pss, analyzing the factors that affect the prognosis of pss, studying the association of its pathogenesis with the psychological status and the behavioral types of pss patients; exploring the relationship between infection (cmv, hsv, hp) and pss; and studying the changes of local and systemic cytokine expression and its significance in patients with pss.


Eligibility criteria:
inclusion criteria: * volunteer to take part in this study and sign informed consent by oneself or the patient's legal representative * clinical diagnosis of posner-schlossman syndrome, age-related cataract, or primary open-angle glaucoma * live in beijing, china or being able to visit the peking university third hospital every year after the beginning of the study or whenever the disease relapses exclusion criteria: * fit any exclusion criteria of the patient's group

Keywords: posner schlossman syndrome cytokine expression cytomegalovirus
colon erderly low dose

Conditions: Colon Adenocarcinoma

Summary: in this retrospective observational study, the case series of patients undergoing first-line treatment for metastatic colorectal adenocarcinoma with doublet fixed-dose and reduced-dose chemotherapy in combination with full-dose monoclonal antibody in patients aged 70 years or older is collected.

treatment in the elderly first-line patient of metastatic colorectal cancer is often conditioned by the age and general condition of the patient. such treatment involves the combination of chemotherapy and biological therapy targeted on the basis of the site and genetic mutations of the colorectal tumour, in particular ras and braf. with regard to targeted biologic therapy, the choice of monoclonal antibody is determined by tumour site and mutations. in particular, for right-sided and/or ras/braf mutated tumours anti-vegf therapy with bevacizumab is the best option, whereas for left-sided and ras/braf wt tumours monoclonal antibodies panitumunab or cetuximab are the choice. in the elderly patient, the intensity of chemotherapy to be combined with targeted biologic therapy varies according to the patient's age, general condition and treatment goals. in particular for patients aged 70 years or older, a valid option is the combination of monochemotherapy with fluorodrugs in combination with bevacizumab. in addition, an italian randomised trial tested monochemotherapy with 5-fluorouracil in combination with panitumumab in ras wt/braf wt tumours and obtained the same efficacy as a doublet of chemotherapy with folfox also in combination with panitumumab. full-dose doublet chemotherapy is hardly feasible in the elderly patient because of the frailty of these patients and the high risk of toxicity. in this retrospective observational study, we report on the case series of patients undergoing first-line treatment for metastatic colorectal adenocarcinoma with doublet of fixed-dose and reduced-dose chemotherapy in combination with full-dose monoclonal antibody in patients 70 years of age and older.

Eligibility criteria:
inclusion criteria: 1. patients with metastatic colorectal adenocarcinoma not treated with any therapy in the metastatic phase. previous (neo)-adjuvant treatment with fluoroderivatives with or without oxaliplatin is permitted. 2. age ≥ 70 years 3. g8 score ≥ 12 4. patients with colorectal adenocarcinoma mss 5. patients with braf wt colorectal adenocarcinoma 6. ability to understand and sign the informed consent form. exclusion criteria: 1. patients with msi tumours 2. patients with braf v600e mutated tumours 3. patients not eligible for doublet chemotherapy by clinical decision

Keywords: metastatic colorectal adenocarcinom low doses chemotherapy monoclonal antibodies
betaferon use in children and adolescents with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the objective of this study is to determine efficacy, safety and tolerability of interferon beta-1b for multiple sclerosis (ms) in children and adolescents


Eligibility criteria:
inclusion criteria: * patients with symptoms consistent with the diagnosis of a demyelinating cns disease * patients who received at least one injection of betaferon before age 18 (before their 18th birthday) * recorded use of at least one dose of betaferon before january 1, 2008 exclusion criteria: * diagnosis other then ms or a demyelinating cns disease

Keywords: multiple sclerosis (ms), betaseron, betaferon
psoriasis and non alcoholic steatohepatitis: is there a shared inflammatory network ?

Conditions: Nash

Summary: the study is to assess frequency of nash in psoriatic patient and to measure the level of proinflammatory cytokines including tnfα, interleukin (il)-6 and il-17 and anti-inflammatory cytokines including il10, il35 by elisa.

• psoriasis is a chronic proliferative and inflammatory condition of the skin. it is characterized by erythematous plaques covered with silvery scales, particularly over the extensor surfaces, scalp, and lumbosacral region. the disorder can also affect the joints and eyes. psoriasis has no cure and the disease waxes and wanes with flareups. there are several subtypes of psoriasis but the plaque type is the most common and presents on the trunk, extremities, and scalp. psoriasis has a prevalence ranging from 0.2% to 4.8%. in parallel, nonalcoholic fatty liver disease (nafld) is the most frequent liver disease worldwide, affecting an estimated 30% of the adult population in developed countries. nafld and the metabolic syndrome are mutually and bi-directionally associated, as these two pathologic condition share insulin resistance as a common pathophysiological mechanism. nafld encompasses a spectrum of pathologic conditions ranging from simple steatosis to nonalcoholic steatohepatitis((nash) featuring steatosis associated with inflammatory changes, hepatocellular ballooning and pericellular fibrosis), to advanced fibrosis and cirrhosis. nafld is projected to become the most common indication for liver transplantation in the united states by 2030 . over the last few years, multiple studies have demonstrated that psoriasis is associated with nafld. the majority reported a prevalence of around 50 % (range 14.4 % to 65.5 %) for nafld in psoriatic patients. the contribution of il-17 to the pathogenesis of both psoriasis and nafld is intriguing. th17 cells can be detected in fat tissue and il-17 itself regulates glucose metabolism and adipogenesis. likewise, il-17(a)-secreting th17 cells may promote the progression from simple steatosis to steatohepatitis \[10\] therefore, both psoriasis and nafld pathogenesis seem to be linked to the joint proinflammatory th17 axis (and other cytokines such as tnfα and il-6).

Eligibility criteria:
inclusion criteria: * any naive psoriatic patient above 18 years old. exclusion criteria: * any psoriatic patient who received treatment for psoriasis. * diabetic patients. * patients under 18 years old. * patient's refusal.

Keywords: nash psoriasis
shoulder injury prevention program in swimmers

Conditions: Shoulder Injury

Summary: the primary purpose of this study is to assess changes in shoulder muscle strength, shoulder movement, shoulder flexibility, muscle thickness, upper arm torsion angle, and subacromial width (space where the rotator cuff muscle passes through) after completing a 6-week shoulder strengthening and stretching program in division i collegiate swimmers. the result of this study may demonstrate the effectiveness of a strengthening and stretching program to positively influence factors that have been associated with pain and injury in division i collegiate swimmers and indicate the need to implement this program for the entire team. following a 6-week strengthening and stretching program, it is believed that scapular kinematics, shoulder flexibility, and shoulder and scapular stabilizer strength will be improved compared to control subjects.


Eligibility criteria:
inclusion criteria: * subjects will be included in the study if they meet the following criteria: * ncaa division i swimmers * participate in swimming for at least 30 minutes per day for 4 days per week. * participate in all team weight lifting sessions. * complete 15 of the 18 training sessions if the subject is placed in the treatment group. exclusion criteria: * subjects will be excluded from the study if: * they are currently being treated for shoulder pain * they develop shoulder pain during the course of the intervention program

Keywords: tubing program shoulder strengthening injury prevention
computer aided detection, tandem colonoscopy study

Conditions: Colonic Diseases

Summary: the purpose of this project is to examine the role of machine learning and computer aided diagnostics in automatic polyp detection and to determine in real-time how a computer-aided detection (cade) algorithm will perform when compared to standard screening or surveillance colonoscopy alone. design will be a multi-center, prospective, unblinded randomized tandem colonoscopy study. 196 patients referred for either screening or surveillance colonoscopy will be included.


Eligibility criteria:
inclusion criteria: * patients presenting to the endoscopy unit for a screening colonoscopy or a surveillance colonoscopy * willingness to undergo tandem colonscopies with and without the use of computer-aided software while undergoing conventional colonoscopy with sedation * ability to provide written, informed consent (approved by irb) and understand the responsibilities of trial participation exclusion criteria: * people with diminished cognitive capacity * patients undergoing diagnostic colonoscopy (e.g. as an evaluation for active gi bleed) * patients with incomplete colonoscopies (those where endoscopists did not successfully intubate the cecum due to technical difficulties or poor bowel preparation) * patients that have standard contraindications to colonoscopy in general (e.g. documented acute diverticulitis, fulminant colitis and known or suspected perforation). * patients with inflammatory bowel disease * patients referred for endoscopic mucosal resection (emr)